Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qinghong Han

Showing results (91-100 of 143) with videos related to

Pageof 15
Sort By:
Cancer Genomics & Proteomics|February 20, 2021
Combination Methionine-methylation-axis Blockade: A Novel Approach to Target the Methionine Addiction of CancerTakashi Higuchi, Qinghong Han, Norihiko Sugisawa, et al.
Tissue & Cell|November 25, 2019
Oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil regressed a colon cancer growing on the peritoneal surface in a patient-derived orthotopic xenograft mouse modelJun Ho Park, Qinghong Han, Ming Zhao, et al.
In Vivo (Athens, Greece)|February 26, 2025
HT1080 Fibrosarcoma With Acquired Trabectedin Resistance: Increased Malignancy But Sustained Sensitivity to Methionine RestrictionSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research|March 4, 2025
Highly Synergistic Eradication of 143B Osteosarcoma Cells <i>In Vitro</i> by the Combination of Recombinant Methioninase, Chloroquine, and Rapamycin Targeting Methionine Addiction, Autophagy, and mTOR, RespectivelySei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research|December 31, 2024
Ivermectin Combined With Recombinant Methioninase (rMETase) Synergistically Eradicates MiaPaCa-2 Pancreatic Cancer CellsSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
In Vivo (Athens, Greece)|April 28, 2025
HT1080 Human Fibrosarcoma Cells Selected for Super-eribulin Resistance <i>In Vitro</i> Become More Malignant and Are Arrested Synergistically by Methionine Restriction in Combination With Eribulin in Nude MiceSei Morinaga, Kohei Mizuta, Byung Mo Kang, et al.
In Vivo (Athens, Greece)|May 2, 2020
Oral Recombinant Methioninase Prevents Nonalcoholic Fatty Liver Disease in Mice on a High Fat DietYoshihiko Tashiro, Qinghong Han, Yuying Tan, et al.
Cell Cycle (Georgetown, Tex.)|April 7, 2018
Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancerKei Kawaguchi, Kentaro Miyake, Qinghong Han, et al.
Frontiers in Oncology|December 24, 2025
Human fibrosarcoma cells selected for ultra-high doxorubicin resistance, acquire trabectedin cross-resistance, remain sensitive to recombinant methioninase, and have increased c-MYC expressionSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
In Vivo (Athens, Greece)|December 31, 2024
Synergistic Eradication of Fibrosarcoma With Acquired Ifosfamide Resistance Using Methionine Restriction Combined With Ifosfamide in Nude-mouse ModelsSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Pageof 15

Showing results (91-100 of 143) with videos related to

Sort By:
Pageof 15
Cancer Genomics & Proteomics|February 20, 2021
Combination Methionine-methylation-axis Blockade: A Novel Approach to Target the Methionine Addiction of CancerTakashi Higuchi, Qinghong Han, Norihiko Sugisawa, et al.
Tissue & Cell|November 25, 2019
Oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil regressed a colon cancer growing on the peritoneal surface in a patient-derived orthotopic xenograft mouse modelJun Ho Park, Qinghong Han, Ming Zhao, et al.
In Vivo (Athens, Greece)|February 26, 2025
HT1080 Fibrosarcoma With Acquired Trabectedin Resistance: Increased Malignancy But Sustained Sensitivity to Methionine RestrictionSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research|March 4, 2025
Highly Synergistic Eradication of 143B Osteosarcoma Cells <i>In Vitro</i> by the Combination of Recombinant Methioninase, Chloroquine, and Rapamycin Targeting Methionine Addiction, Autophagy, and mTOR, RespectivelySei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research|December 31, 2024
Ivermectin Combined With Recombinant Methioninase (rMETase) Synergistically Eradicates MiaPaCa-2 Pancreatic Cancer CellsSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
In Vivo (Athens, Greece)|April 28, 2025
HT1080 Human Fibrosarcoma Cells Selected for Super-eribulin Resistance <i>In Vitro</i> Become More Malignant and Are Arrested Synergistically by Methionine Restriction in Combination With Eribulin in Nude MiceSei Morinaga, Kohei Mizuta, Byung Mo Kang, et al.
In Vivo (Athens, Greece)|May 2, 2020
Oral Recombinant Methioninase Prevents Nonalcoholic Fatty Liver Disease in Mice on a High Fat DietYoshihiko Tashiro, Qinghong Han, Yuying Tan, et al.
Cell Cycle (Georgetown, Tex.)|April 7, 2018
Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancerKei Kawaguchi, Kentaro Miyake, Qinghong Han, et al.
Frontiers in Oncology|December 24, 2025
Human fibrosarcoma cells selected for ultra-high doxorubicin resistance, acquire trabectedin cross-resistance, remain sensitive to recombinant methioninase, and have increased c-MYC expressionSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
In Vivo (Athens, Greece)|December 31, 2024
Synergistic Eradication of Fibrosarcoma With Acquired Ifosfamide Resistance Using Methionine Restriction Combined With Ifosfamide in Nude-mouse ModelsSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Pageof 15